Loading
Imagene AI
Imagene AI Ltd. is an innovative artificial intelligence company based in Tel Aviv, Israel, with additional operations in Miami, Florida, and Phoenix, Arizona. Founded in 2020 by Dean Bitan, the company focuses on precision oncology and digital biomarker discovery. Imagene AI utilizes its proprietary Cross-Modality Intelligence Engine to enhance cancer diagnostics by analyzing digitized biopsy images alongside molecular and clinical data. This approach helps identify complex patterns and cancerous biomarkers, facilitating faster and more accurate diagnoses. The company offers a range of advanced services for biopharma companies, clinical institutions, and medical centers. These include AI-based molecular testing for cancer, biomarker discovery, clinical trial optimization, and rapid molecular screening that significantly reduces diagnostic turnaround time. Imagene AI's product portfolio features the OI Suite, a SaaS platform for oncology applications, and specific tests like LungOI, which provides rapid biomarker profiling for lung cancer. The company collaborates with leading healthcare institutions and pharmaceutical firms to drive advancements in precision medicine.
Funding
Every round, secondary, debt facility or acquisition involving Imagene AI that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$1M